Furthermore, this study showed that MG1 treatment induced a memory immune response, providing protection against the tumor, suggesting the potential use of rabdovirus MG1 as oncolytic immunotherapy in sarcoma treatment (alone or in combination with other therapeutic strategies). Here, MUC5B is linked to sarcoma.